Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the multiple myeloma market size evolved in recent years?

The size of the multiple myeloma market has seen substantial growth in the recent past. The market value is expected to rise from $26.07 billion in 2024 to $28.15 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.0%. The impressive growth during the historic period is due to enhanced diagnostic techniques, the onset of stem cell transplantation, availability of superior medical care, precision medicine strategies, and patient-focused care models.

What are the predictions for the multiple myeloma market size in the coming years?

In the coming years, a considerable surge is anticipated in the size of the multiple myeloma market. It is forecasted to expand to $38.39 billion in 2029, with a compound annual growth rate (CAGR) of 8.1%. The upswing during the projected period can be credited to the amalgamation of health technology, utilization of telemedicine services, tailor-made vaccine therapies, and digital health platforms aimed at patient education. Progressive strides in targeted treatments, pioneering drug formulation, breakthroughs in immunotherapy, innovative biomarker formulation, and employment of artificial intelligence are significant trends anticipated in the forecast period.

Get your multiple myeloma market report here!

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

What key factors are fueling the growth of the multiple myeloma market?

The surge in instances of multiple myeloma is predicted to stimulate the expansion of the multiple myeloma market. Multiple myeloma is a type of cancer that originates in a kind of white blood cell named plasma cell. Factors contributing to the rise of this disease include age, genetics, obesity, exposure to radiation, and other conditions. Treatment for multiple myeloma aims to slow its progression and alleviate symptoms. For example, data from the American Cancer Society, a voluntary health organization based in the US, reported an increase in new multiple myeloma cases to 35,730 in 2023, up from 34,470 in 2022. Thus, the escalating prevalence of multiple myeloma is fueling the advancement of the multiple myeloma market.

How is the global multiple myeloma market divided into key segments?

The multiple myeloma market covered in this report is segmented –

1) By Treatment: Medications, Radiation Therapy, Stem Cell Transplant, Other Treatments

2) By Diagnosis: Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests

3) By Disease Type: Active Multiple Myeloma, Smoldering Multiple Myeloma

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Channels

Subsegments:

1) By Medications: Immunomodulatory Drugs (IMiDs), Proteasome Inhibitors, Monoclonal Antibodies, Corticosteroids, Chemotherapy Agents

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioisotope Therapy

3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT), Allogeneic Stem Cell Transplant

4) By Other Treatments: Supportive Care, Clinical Trials And Experimental Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12163&type=smp

Who are the key firms paving the way for growth in the multiple myeloma market?

Major companies operating in the multiple myeloma market include Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Mylan N.V., Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., CRISPR Therapeutics AG, Karyopharm Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Allogene Therapeutics Inc., C4 Therapeutics Inc., Adaptimmune Therapeutics plc, Precision Biosciences Inc.

Which trends are expected to transform the multiple myeloma market?

One significant trend becoming increasingly prevalent in the multiple myeloma market is product innovation. Companies of considerable stature in the multiple myeloma market concentrate their efforts on creating novel products to maintain their market dominance. Take for example, Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical firm based in Belgium, which secured approval for TECVAYLI (teclistamab-cqyv), the inaugural bispecific T-cell engager antibody, granted by the US Food and Drug Administration in October 2022. This medication is designed to treat adult patients with multiple myeloma, who have undergone at least four previous lines of therapy, including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies targeting CD38. Its mechanism of action involves targeting the B-cell maturation antigen (BCMA), present on some healthy B-lineage cells’ surface, and the CD3 receptor found on T-cells’ surface and multiple myeloma cells.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12163

What regions are contributing significantly to the growth of the multiple myeloma market?

North America was the largest region in the multiple myeloma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Land Planning And Development Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/land-planning-and-development-global-market-report

Industrial Land Planning And Development Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/industrial-land-planning-and-development-global-market-report

Recreation Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/recreation-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: